Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review
- PMID: 15200577
- DOI: 10.1111/j.1360-0443.2004.00763.x
Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review
Erratum in
- Addiction. 2005 Apr;100(4):573. Magro, Angeles [corrected to Angeles, Magro]
Abstract
Aims: To ascertain the efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence.
Methods: Systematic review of the literature (1990-2002) and meta-analysis of full published randomized and controlled clinical trials assessing acamprosate or naltrexone therapy in alcohol dependence. Estimates of effect were calculated according to the fixed-effects model.
Measurements: Relapse and abstinence rates, cumulative abstinence duration and treatment compliance were considered as primary outcomes. Findings Thirty-three studies met the inclusion criteria. Acamprosate was associated with a significant improvement in abstinence rate [odds ratio (OR): 1.88 (1.57, 2.25), P < 0.001] and days of cumulative abstinence [WMD: 26.55 (17.56, 36.54]. Short-term administration of naltrexone reduced the relapse rate significantly [OR: 0.62 (0.52, 0.75), P < 0.001], but was not associated with a significant modification in the abstinence rate [OR: 1.26 (0.97,1.64), P = 0.08]. There were insufficient data to ascertain naltrexone's efficacy over more prolonged periods. Acamprosate had a good safety pattern and was associated with a significant improvement in treatment compliance [OR: 1.29 (1.13,1.47), P < 0.001]. Naltrexone's side effects were more numerous, yet the drug was nevertheless tolerated acceptably without being associated with a lower adherence to treatment (OR: 0.94 (0.80, 1.1), P = 0.5). However, overall compliance was relatively low with both medications.
Conclusions: Both acamprosate and naltrexone are effective as adjuvant therapies for alcohol dependence in adults. Acamprosate appears to be especially useful in a therapeutic approach targeted at achieving abstinence, whereas naltrexone seems more indicated in programmes geared to controlled consumption. Both drugs are safe and acceptably tolerated but issues of compliance need to be addressed adequately to assure their usefulness in clinical practice.
Comment in
-
Review: acamprosate and naltrexone are safe and effective but have low compliance rates for people with alcohol dependence.Evid Based Ment Health. 2005 Feb;8(1):14. doi: 10.1136/ebmh.8.1.14. Evid Based Ment Health. 2005. PMID: 15671505 No abstract available.
Similar articles
-
The efficacy of acamprosate and naltrexone in the treatment of alcohol dependence, Europe versus the rest of the world: a meta-analysis.Addiction. 2015 Jun;110(6):920-30. doi: 10.1111/add.12875. Epub 2015 Mar 17. Addiction. 2015. PMID: 25664494
-
Opioid antagonists for alcohol dependence.Cochrane Database Syst Rev. 2002;(2):CD001867. doi: 10.1002/14651858.CD001867. Cochrane Database Syst Rev. 2002. Update in: Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001867. doi: 10.1002/14651858.CD001867.pub2. PMID: 12076425 Updated.
-
Oral naltrexone as a treatment for relapse prevention in formerly opioid-dependent drug users: a systematic review and economic evaluation.Health Technol Assess. 2007 Feb;11(6):iii-iv, 1-85. doi: 10.3310/hta11060. Health Technol Assess. 2007. PMID: 17280624
-
Opioid antagonists for alcohol dependence.Cochrane Database Syst Rev. 2005 Jan 25;(1):CD001867. doi: 10.1002/14651858.CD001867.pub2. Cochrane Database Syst Rev. 2005. Update in: Cochrane Database Syst Rev. 2010 Dec 08;(12):CD001867. doi: 10.1002/14651858.CD001867.pub3. PMID: 15674887 Updated.
-
Opioid antagonists for alcohol dependence.Cochrane Database Syst Rev. 2000;(3):CD001867. doi: 10.1002/14651858.CD001867. Cochrane Database Syst Rev. 2000. Update in: Cochrane Database Syst Rev. 2002;(2):CD001867. doi: 10.1002/14651858.CD001867. PMID: 10908513 Updated.
Cited by
-
Gabapentin for Post-Hospitalization Alcohol Relapse Prevention; Should Gabapentin Be Considered for FDA Approval in the Treatment of Alcohol Use Disorder?: A Case Presentation and Literature Review.Cureus. 2020 Jun 30;12(6):e8931. doi: 10.7759/cureus.8931. Cureus. 2020. PMID: 32760631 Free PMC article.
-
The BDNF Valine 68 to Methionine Polymorphism Increases Compulsive Alcohol Drinking in Mice That Is Reversed by Tropomyosin Receptor Kinase B Activation.Biol Psychiatry. 2016 Mar 15;79(6):463-73. doi: 10.1016/j.biopsych.2015.06.007. Epub 2015 Jun 12. Biol Psychiatry. 2016. PMID: 26204799 Free PMC article.
-
Mu-opioid receptor activation in the medial shell of nucleus accumbens promotes alcohol consumption, self-administration and cue-induced reinstatement.Neuropharmacology. 2016 Sep;108:14-23. doi: 10.1016/j.neuropharm.2016.04.010. Epub 2016 Apr 14. Neuropharmacology. 2016. PMID: 27089981 Free PMC article.
-
Comparison of healthcare utilization among patients treated with alcoholism medications.Am J Manag Care. 2010;16(12):879-88. Am J Manag Care. 2010. PMID: 21348558 Free PMC article.
-
A longitudinal examination of alcohol pharmacotherapy adoption in substance use disorder treatment programs: patterns of sustainability and discontinuation.J Stud Alcohol Drugs. 2011 Jul;72(4):669-77. doi: 10.15288/jsad.2011.72.669. J Stud Alcohol Drugs. 2011. PMID: 21683049 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous